Lamotrigin Desitin® (Plexxo®) - the special generic product - Value in Epilepsy Therapy

Financial pressures in public health are persistently on the increase. One consequence thereof is the rising use of longestablished generic products for several indications. In the field of anti-epileptic therapy as well, we find an increasing number of generic successor products in the market. The question of dealing with generic products in the specific target group of epilepsy patients is of great significance for the neurologist. The risks associated with switching between different commercial drugs based on a specific active substance must be justifiably low from the perspective of the treating physician as well as the perspective of the affected patient. The editorial office of NeuroNews had an opportunity to conduct an exclusive interview on this subject with Prof. C. Elger, Director of the Department of Epileptology at the University Clinic of Bonn. In addition to the general problem of substitution of generic products in epilepsy treatment, the conversation was focused on the active substance lamotrigine which is being offered in the German market by several companies, e.g. Desitin Arzneimittel GmbH since June 2005 in the form of various generic products. The trade name for Lamotrigin Desitin® in Czech Republic, Romania, Poland, Hungary and Slovakia is called Plexxo®. All dosage strengths of Plexxo® tablets are divisible.

full article